Clinical trial results:
A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active psoriatic arthritis

Summary

EudraCT number	2016-003637-14
Trial protocol	EE ES CZ BE BG
Global end of trial date	12 March 2018

Results information

Result version number	v1 (current)
This version publication date	23 March 2019
First version publication date	23 March 2019

Trial information

Trial identification

Sponsor protocol code	GLPG0634-CL-224

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03101670
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Galapagos NV
Sponsor organisation address	Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
Public contact	Clinical Trial Information Desk, Galapagos NV, +32 15342 900, rd@glpg.com
Scientific contact	Clinical Trial Information Desk, Galapagos NV, +32 15342 900, rd@glpg.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 October 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	12 March 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Primary Objective:
- Evaluate the effect of filgotinib compared to placebo on the signs and symptoms of peripheral arthritis, as assessed by the ACR20 at Week 16.

Secondary Objectives:
- Evaluate the effect of filgotinib compared to placebo on:
  - The signs and symptoms of psoriatic arthritis (PsA)
  - The signs and symptoms of peripheral arthritis
  - Psoriasis
  - Enthesitis
  - Dactylitis
  - Physical function
  - Fatigue and general quality of life
- Evaluate the safety and tolerability of filgotinib

Protection of trial subjects:

Study GLPG0634-CL-224 was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Council for Harmonisation (ICH) guideline for Good Clinical Practice (GCP) (Sections 7.6 and 8.2) and the original principles embodied in the Declaration of Helsinki. These standards are consistent with the requirements of the European Community Directive 2001/20/EC. For Ukraine, standards are in accordance with Ukraine Guidance "Medicinal Products. Good clinical practice СТ-Н МОЗУ 42-7.0:2008" approved by MoH Order of 16.02.2009 № 95 and with consideration of requirements of Directive 2001/20/EC.

The investigator (or designee) was responsible for obtaining written informed consent from each individual who participated in this study after adequate explanation of the aims, methods, objectives, and potential hazards of the study and before undertaking any study-related procedures. Subjects were informed that they were completely free to refuse to enter the study or to withdraw from it at any time for any reason.

Background therapy: -
Evidence for comparator: -

Actual start date of recruitment	09 March 2017
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	3 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 35
Country: Number of subjects enrolled	Spain: 11
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Bulgaria: 12
Country: Number of subjects enrolled	Czech Republic: 6
Country: Number of subjects enrolled	Estonia: 15
Country: Number of subjects enrolled	Ukraine: 51
Worldwide total number of subjects	131
EEA total number of subjects	80

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	118
From 65 to 84 years	13
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted from 09-March-2017 to 12-March-2018 in 25 investigational sites in 7 countries: Bulgaria, Czech Republic, Estonia, Poland, Ukraine, Belgium and Spain.

Pre-assignment

Screening details:

In total, 191 subjects were screened, of whom 131 were randomized and received at least one dose of study drug.

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Filgotinib

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Filogotinib
Investigational medicinal product code	GLPG0634
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 filgotinib 200 mg tablet once daily for 16 weeks.

Arm title	Placebo

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 placebo tablet once daily for 16 weeks.

Number of subjects in period 1	Filgotinib	Placebo
Started	65	66
Completed	60	64
Not completed	5	2
Adverse event, serious fatal	1	-
Consent withdrawn by subject	2	1
Adverse event, non-fatal	1	-
Lack of efficacy	1	1

Baseline characteristics

Reporting groups	
Reporting group title	Filgotinib
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	Filgotinib	Placebo	Total
Number of subjects	65	66	131
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	58	60	118
From 65-84 years	7	6	13
85 years and over	0	0	0
Age continuous Units: years			
median	49	51	
full range (min-max)	22 to 69	23 to 72	-
Gender categorical Units: Subjects			
Female	36	30	66
Male	29	36	65
Race Units: Subjects			
White	65	66	131
BMI Units: kg/m²			
median	27.85	29.45	
full range (min-max)	17.17 to 51.05	19.38 to 52.12	-

End points

End points reporting groups

Reporting group title	Filgotinib
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Primary: American College of Rheumatology 20% improvement (ACR20) Response

End point title	American College of Rheumatology 20% improvement (ACR20) Response

End point description:

The signs and symptoms of peripheral arthritis were measured using ACR20.
The primary end point was the percentage of subjects achieving ACR20 at Week 16.

A subject achieved ACR20 response when this subject had:
- ≥ 20% improvement from baseline in the 68 tender joint count (TJC68), and
- ≥ 20% improvement from baseline in the 66 swollen joint count (SJC66), and
- ≥ 20% improvement from baseline in at least 3 of the following 5 criteria:
 - Patient’s Global Assessment of Disease Activity (PGADA) (0–100 mm visual analog scale (VAS))
 - Physician's Global Assessment of Disease Activity (PhGADA) (0–100 mm VAS)
 - Patient’s Global Assessment of psoriatic arthritis (PsA) pain intensity (0–100 mm VAS)
 - Patient’s assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) score
 - C-Reactive Protein (CRP)

End point type	Primary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: percent				
number (confidence interval 95%)				
Week 16	80.0 (68.73 to 87.92)	33.3 (23.16 to 45.34)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

ACR20 Response Rate difference at Week 16 (NRI)

Comparison groups	Filgotinib v Placebo

Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	46.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	30.2
upper limit	59.56

Secondary: Minimal Disease Activity (MDA) Response

End point title	Minimal Disease Activity (MDA) Response

End point description:

The disease activity in PsA was measured using the MDA, which is a measure to indicate disease remission. The endpoint was the percentage of subjects achieving MDA at Week 16.

A subject was classified as having achieved MDA when at least 5 out of 7 of the following criteria were met:
- TJC68 ≤ 1
- SJC66 ≤ 1
- Psoriasis Area and Severity Index (PASI) ≤ 1 for subjects with a baseline affected Body Surface Area (BSA) of ≥ 3% (or for subjects with a baseline affected BSA < 3%, this criterion was considered met)
- Patient's Global Assessment of PsA pain intensity score ≤ 15 (0 to 100 mm VAS)
- PGADA ≤ 20 (0 to 100 mm VAS)
- HAQ-DI ≤ 0.5
- Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index ≤ 1 for subjects with enthesitis (SPARCC Enthesitis Index > 0) at baseline (or for subjects without enthesitis [SPARCC = 0] at baseline, this criterion was considered met).

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: percent				
number (confidence interval 95%)				
Week 16	23.1 (14.51 to 34.64)	9.1 (4.23 to 18.45)		

Statistical analyses

Statistical analysis title	Treatment difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

MDA Response Rate difference at Week 16 (NRI)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0212
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	14
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	26.53

Secondary: ACR50/70 Response

End point title	ACR50/70 Response

End point description:

ACR50 and ACR70 were derived using the same algorithm as ACR20, but with 50% and 70% cut-offs, respectively. The endpoint was the percentage of subjects achieving ACR50/70 at Week 16.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: percent				
number (confidence interval 95%)				
ACR50 Week 16	47.7 (36.02 to 59.62)	15.2 (8.44 to 25.69)		
ACR70 Week 16	23.1 (14.51 to 34.64)	6.1 (2.38 to 14.57)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

ACR50 Response Rate difference at Week 16 (NRI)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	32.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.81
upper limit	46.23

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

ACR70 Response Rate difference at Week 16 (NRI)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Response Rate Difference
Point estimate	17
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.94
upper limit	29.15

Secondary: Disease Activity Score for 28 joint count using C-reactive protein - DAS28(CRP)

End point title	Disease Activity Score for 28 joint count using C-reactive protein - DAS28(CRP)

End point description:

The DAS28(CRP) is a composite score combining several parameters.

DAS28(CRP) was calculated as follows:
DAS28(CRP) = 0.56 × √TJC28 + 0.28 × √SJC28 + 0.36 × Ln(CRP + 1) + 0.014 × PGADA + 0.96
Where:
- Ln(CRP + 1) is the natural logarithm of (CRP value [mg/L] + 1)
- PGADA is on a 0 to 100 mm VAS scale.

The DAS28(CRP) could range from 2 to 10, with a higher value indicating a more severe disease activity status.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	4.9 (± 1.00)	5.1 (± 1.04)		
Week 16	2.9 (± 1.09)	4.1 (± 1.22)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

Comparison of DAS28(CRP) change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	-1.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.45
upper limit	-0.78
Variability estimate	Standard error of the mean
Dispersion value	0.17

Secondary: Simplified Disease Activity Index (SDAI)

End point title	Simplified Disease Activity Index (SDAI)

End point description:

The SDAI is a composite score of 5 outcome parameters.
SDAI = TJC28 + SJC28 + PGADA (0 to 10 cm VAS) + PhGADA (0 to 10 cm VAS) + CRP (mg/dL)

This index has no bounds and higher scores indicate more severe disease activity.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	31.0 (± 10.96)	33.7 (± 12.40)		
Week 16	11.4 (± 8.13)	21.8 (± 12.59)		

Statistical analyses

Statistical analysis title	Treatment difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

SDAI difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	-9.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.44
upper limit	-6.08
Variability estimate	Standard error of the mean
Dispersion value	1.61

Secondary: Clinical Disease Activity Index (CDAI)

End point title	Clinical Disease Activity Index (CDAI)

End point description:

The CDAI is a further simplification of SDAI (excluding CRP):
CDAI = TJC28 + SJC28 + PGADA (0 to 10 cm VAS) + PhGADA (0 to 10 cm VAS)
The CDAI could range from 0 to 76, with a higher score indicating a more severe disease activity status.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	29.7 (± 10.36)	32.6 (± 11.83)		
Week 16	11.1 (± 7.96)	20.6 (± 11.87)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

Comparison of CDAI change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	-8.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.33
upper limit	-5.16
Variability estimate	Standard error of the mean
Dispersion value	1.56

Secondary: European League Against Rheumatism (EULAR) response and remission

End point title	European League Against Rheumatism (EULAR) response and remission

End point description:

The end point was the percentage of subjects achieving EULAR response (good, moderate or none) or EULAR remission at Week 16.

DAS28 (CRP) was categorized into EULAR response categories (none, moderate, good) as follows:
Good = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline > 1.2;
Moderate = Actual DAS28 (CRP) ≤ 3.2 AND Improvement in DAS28 (CRP) from baseline > 0.6 to ≤ 1.2, Actual DAS28 (CRP) > 3.2 to ≤ 5.1 or > 5.1 AND Improvement in DAS28 (CRP) from baseline > 1.2, or Actual DAS28 (CRP) > 3.2 to ≤ 5.1 AND Improvement in DAS28 (CRP) from baseline > 0.6 to ≤ 1.2.
None = Actual DAS28 (CRP) > 5.1 AND Improvement in DAS28 (CRP) from baseline > 0.6 to ≤ 1.2; Improvement in DAS28 (CRP) from baseline ≤ 6.0 irrespective of the Actual DAS28 (CRP);

EULAR remission was defined when scores on TJC28, SJC28, CRP, and PGADA were all ≤ 1.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: percent				
number (not applicable)				
EULAR Response Week 16 - Good	56.9	15.2		
EULAR Response Week 16 - Moderate	35.4	39.4		
EULAR Response Week 16 - None	7.7	45.5		
EULAR Remission Week 16	6.2	3.0		

Statistical analyses

Statistical analysis title	EULAR remission at Week 16

Statistical analysis description:

Comparison of EULAR remission at Week 16 between the 2 arms (Filgotinib – Placebo) (NRI)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3655
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.13
upper limit	12.03

Secondary: Psoriatic Arthritis Response Criteria (PsARC)

End point title	Psoriatic Arthritis Response Criteria (PsARC)

End point description:

The end point was the percentage of subjects achieving PsARC response at Week 16.

A PsARC responder was defined as having an improvement in ≥ 2 of the 4 factors (with at least one factor being a joint count) and no worsening in the remaining factors:
- TJC68 (improvement defined as a decrease from baseline of ≥ 30%)
- SJC66 (improvement defined as a decrease from baseline of ≥ 30%)
- PGADA (0 to 100 mm VAS, improvement defined as a decrease from baseline of ≥ 20 mm)

- PhGADA (0 to 100 mm VAS, improvement defined as a decrease from baseline of ≥ 20 mm)

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: percent				
number (confidence interval 95%)				
Week 16	80.0 (68.73 to 87.92)	47.0 (35.43 to 58.84)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

PsARC difference at Week 16 (NRI).

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Mean difference (final values)
Point estimate	33
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.66
upper limit	47.03

Secondary: Physician’s Global Assessment of Disease Activity (PhGADA)

End point title	Physician’s Global Assessment of Disease Activity (PhGADA)

End point description:

Global assessment of the subject’s arthritis disease activity was performed by the physician having access to the joint assessments. A perpendicular line was drawn on the VAS, and the distance between the “no disease activity” anchor and the mark on the 10-cm line in mm (with the end indicating “extreme disease activity”) was the score from 0-100.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: mm				
arithmetic mean (standard deviation)				
Baseline	66.1 (± 15.01)	66.0 (± 15.31)		
Week 16	21.4 (± 15.35)	40.7 (± 20.70)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

PhGADA difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	-19.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.85
upper limit	-13.66
Variability estimate	Standard error of the mean
Dispersion value	3.08

Secondary: Patient's Global Assessment of Disease Activity (PGADA)

End point title	Patient's Global Assessment of Disease Activity (PGADA)

End point description:

The subject's global assessment of their arthritis disease activity was recorded on a 0 to 100 mm VAS. A perpendicular line was drawn on the VAS, and the distance between the beginning of the line and the mark on the 10-cm line in mm was the score from 0-100. A score of 0 indicated "very well" and 100 indicated "very poor" to the question "Considering all the ways psoriatic arthritis affects you, how well are you doing today?"

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: mm				
arithmetic mean (standard deviation)				
Baseline	61.8 (± 17.25)	63.3 (± 18.97)		
Week 16	34.5 (± 19.83)	49.8 (± 22.78)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

PGADA difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-15.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.27
upper limit	-8.1
Variability estimate	Standard error of the mean
Dispersion value	3.58

Secondary: Patient's Global Assessment of PsA pain intensity

End point title	Patient's Global Assessment of PsA pain intensity

End point description:

The patient’s assessment of pain was performed using a 0-100 mm VAS ranging from “no pain” to “unbearable pain” after the question “Please indicate with a vertical mark (|) through the horizontal line the most pain you had from your psoriatic arthritis today”. The length of the line from 0 to the patient’s mark was recorded. This assessment was completed before the joint examination. This pain score was also used to derive the ACR20/50/70.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: mm				
arithmetic mean (standard deviation)				
Baseline	65.2 (± 16.65)	61.5 (± 21.57)		
Week 16	33.6 (± 21.66)	50.5 (± 25.61)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

Patient PsA Pain Difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-18.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.65
upper limit	-11.1
Variability estimate	Standard error of the mean
Dispersion value	3.93

Secondary: 66/68-Joint Count

End point title	66/68-Joint Count

End point description:

Each of 66 joints were evaluated for swelling (SJC66) and each of 68 joints for tenderness (TJC68).

The assessment for each joint was from the following selections: tender only, swollen only, tender and swollen, asymptomatic, temporarily not assessable, or permanently not assessable. Both "temporarily not assessable" and "permanently not assessable" selections were treated as missing assessments.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: Joint Count				
arithmetic mean (standard deviation)				
TJC68 - Baseline	18.3 (± 9.23)	21.6 (± 13.19)		
TJC68 - Week 16	6.2 (± 6.80)	12.6 (± 9.43)		
SJC66 - Baseline	11.6 (± 5.12)	12.7 (± 6.69)		
SJC66 - Week 16	2.7 (± 4.13)	5.9 (± 7.00)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

TJC68 difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-5.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.89
upper limit	-2.74
Variability estimate	Standard error of the mean
Dispersion value	1.3

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

SJC66 difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo

Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0039
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-2.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.39
upper limit	-0.86
Variability estimate	Standard error of the mean
Dispersion value	0.89

Secondary: C-reactive protein (CRP) measurements

End point title	C-reactive protein (CRP) measurements

End point description:

Descriptive statistics for High Sensitivity Serum C-reactive Protein (hsCRP) over time

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: mg/L				
arithmetic mean (standard deviation)				
Baseline	13.9 (± 19.79)	10.9 (± 17.18)		
Week 16	3.0 (± 4.10)	12.6 (± 17.42)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

hsCRP difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo

Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-10.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.3
upper limit	-7.12
Variability estimate	Standard error of the mean
Dispersion value	1.81

Secondary: Psoriasis Area and Severity Index (PASI) Score Including Body Surface Area

End point title	Psoriasis Area and Severity Index (PASI) Score Including Body Surface Area

End point description:

PASI score was used to measure the severity & extent of psoriasis. Psoriasis representative sites were selected for each body region (head [h], upper limbs [u], trunk [t], & lower limbs [l]), & were separately scored by using 3 parameters (erythema [E], infiltration [I] & desquamation [D]), each of which was graded on a severity scale of 0 to 4 (0 = none; 4 = very severe). The area-wise % involvement of the involved sites (head [Ah], upper limbs [Au], trunk [At], & lower limbs [Al]) was calculated as: 0 = no involvement, 1 = < 10%, 2 = 10% to < 30%, 3 = 30% to < 50%, 4 = 50% to < 70%, 5 = 70% to < 90%, & 6 = 90% to 100%.

The formula for PASI score was:
PASI = 0.1 × (Eh + Ih + Dh) × Ah + 0.2 × (Eu + Iu + Du) × Au + 0.3 × (Et + It + Dt) × At + 0.4 × (El + Il + Dl) × Al

The total PASI score ranged from 0 (no disease) to 72 (maximal disease but was considered unreliable when BSA <3).

End point values reported are for the subgroup of subjects who had at least 3% BSA at baseline.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	40		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	10.9 (± 11.73)	11.7 (± 11.85)		
Week 16	4.6 (± 7.11)	8.5 (± 11.00)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

PASI difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.007
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-3.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.09
upper limit	-1
Variability estimate	Standard error of the mean
Dispersion value	1.28

Secondary: Physician’s Global Assessment of Psoriasis (PhGAP)

End point title	Physician’s Global Assessment of Psoriasis (PhGAP)

End point description:

The physician scored the subject’s psoriasis disease activity according to the following grades:
- Induration (I) (0 to 5 scale, averaged over all lesions)
- Erythema (E) (0 to 5 scale, averaged over all lesions)
- Scaling (S) (0 to 5 scale, averaged over all lesions)

The sum of the 3 grades was divided by 3, ie, (I+E+S)/3, and rounded to the nearest integer (ie, 0, 1, 2, 3, 4, 5) to obtain the total average score. Physician’s Static Global Assessment (0-5 scale) was based on the total average score: 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, and 5 = severe.

End point values reported are for the subgroup of subjects who had at least 3% BSA at baseline.

End point type	Secondary

End point timeframe:

Change from baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	40		
Units: score on a scale				
arithmetic mean (standard deviation)				
Total Score (I+E+S)/3 (0-5) - Baseline	2.5 (± 1.15)	2.7 (± 0.97)		
Total Score (I+E+S)/3 (0-5) - Week 16	1.3 (± 0.86)	2.0 (± 0.96)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

PhGAP Total Score ((I+E+S)/3 (0-5)) difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0209
Method	Wilcoxon (Mann-Whitney)

Secondary: Patient's Global Assessment of Psoriasis (PGAP)

End point title	Patient's Global Assessment of Psoriasis (PGAP)

End point description:

PGAP is a 5-point Likert scale (clear, almost clear, mild, moderate, and severe) ranging from 0 indicating "clear" to 4 indicating "severe". The percentage of subjects within these PGAP categories are presented.

End point values reported are for the subgroup of subjects who had at least 3% BSA at baseline.

End point type	Secondary

End point timeframe:

Change from baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	40		
Units: percent				
number (not applicable)				
Baseline - Clear	0	2.5		
Baseline - Almost Clear	0	2.5		
Baseline - Mild	19.0	7.5		
Baseline - Moderate	59.5	60.0		
Baseline - Severe	21.4	27.5		
Week 16 - Clear	9.5	0		

Week 16 - Almost Clear	16.7	12.5		
Week 16 - Mild	35.7	25.0		
Week 16 - Moderate	35.7	45.0		
Week 16 - Severe	2.4	17.5		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

Difference in PGAP change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0166
Method	Wilcoxon (Mann-Whitney)

Secondary: Modified Nail Psoriasis Area and Severity Index (mNAPSI)

End point title	Modified Nail Psoriasis Area and Severity Index (mNAPSI)

End point description:

The mNAPSI was used to assess each nail abnormality for each of the subject's nails. Three features or groups of features (pitting, onycholysis together with oil-drop dyschromia, and crumbling) of each fingernail were graded on a scale from 0 to 3. Four features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula) were graded as either present (1) or absent (0) for each fingernail. Each fingernail had a score between 0 and 13. The total mNAPSI score was the sum of all individual scores of all abnormalities across all fingernails, and ranged from 0 to 130.

End point values are reported for the subgroup of subjects who had psoriatic nails at baseline.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	44	46		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	19.2 (± 24.01)	18.2 (± 17.45)		
Week 16	13.1 (± 21.09)	14.1 (± 12.72)		

Statistical analyses

No statistical analyses for this end point

Secondary: Pruritus numeric rating scale (NRS)

End point title	Pruritus numeric rating scale (NRS)

End point description:

At each study visit, the subject was asked to complete an evaluation of pruritus using a visual rating scale with numbered intervals (integers). The subject rated the intensity of pruritus based on a recall period of 24 hours of the most severe episode of pruritus experienced during that time interval. The subjects were asked to rate their pruritus on a 0 (no itching) to 10 (worst possible itching) scale.

End point values reported are for the subgroup of subjects who had at least 3% BSA at baseline.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	42	40		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	5.4 (± 2.29)	6.0 (± 2.21)		
Week 16	2.9 (± 2.03)	5.4 (± 2.27)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

Pruritus NRS difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	-2.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.06
upper limit	-1.42
Variability estimate	Standard error of the mean
Dispersion value	0.41

Secondary: Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

End point title	Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

End point description:

The enthesitis examination was based on 16 anatomical sites: the medial epicondyle, the lateral epicondyle, the supraspinatus insertion, the bilateral greater trochanter, the quadriceps tendon insertion into superior border of patella, the patellar ligament insertion into inferior pole of patella or tibial tuberosity, the Achilles tendon insertion, and the plantar fascia insertion, all left and right. Tenderness at each site was quantified on a dichotomous basis: 0 means nontender and 1 means tender.
The SPARCC Enthesitis Index was derived as the sum of the tenderness over the 16 sites mentioned above and ranges from 0 to 16.

End point values are reporting for the subgroup of patients who had enthesitis at baseline according to the SPARCC.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	48		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	4.9 (± 2.95)	5.5 (± 3.75)		
Week 16	2.1 (± 2.68)	3.7 (± 3.62)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

SPARCC Enthesitis Index difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.031
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	-1.36

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.59
upper limit	-0.13
Variability estimate	Standard error of the mean
Dispersion value	0.62

Secondary: Leeds Enthesitis Index (LEI)

End point title	Leeds Enthesitis Index (LEI)

End point description:

The medial femoral condyle (left and right), the lateral epicondyle (left and right), and the Achilles tendon insertion (left and right) were used to calculate the LEI, which in turn was required to calculate the PASDAS.

LEI was derived as the sum of the tenderness over the 6 sites mentioned above and ranges from 0 to 6.

End point values are reported for the subgroup of patients who had enthesitis at baseline according to the LEI.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	33	43		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	2.8 (± 1.41)	2.6 (± 1.43)		
Week 16	1.0 (± 1.33)	1.9 (± 1.64)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

LEI difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo

Number of subjects included in analysis	76
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.68
upper limit	-0.5
Variability estimate	Standard error of the mean
Dispersion value	0.29

Secondary: Leeds Dactylitis Index (LDI)

End point title	Leeds Dactylitis Index (LDI)

End point description:

The LDI measured the ratio of the circumference of the affected digit to the circumference of the digit on the contralateral hand or foot using a Leeds Dactylometer.

LDI score of a dactylitic finger/toe = {[(A/B)-1] x 100} × C

Where:
A = circumference of the dactylitic finger/toe (mm)
B = circumference of the contralateral digit (mm)
C = tenderness score (0 = no tenderness, 1 = tender)

If both ipsilateral and contralateral digits were thought to be dactylitic, then the reference value was used as the comparator (ie, B in the above formula). Binary tenderness score was used in LDI score calculation.

The total LDI score equaled to the sum of the nonnegative individual LDI scores across all fingers and toes.

End point values are reported for the subgroup of patients who had dactylitis at baseline according to the LDI. This index has no bounds and higher scores indicate more severe disease activity.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	29		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	40.8 (± 36.06)	39.3 (± 24.66)		
Week 16	3.6 (± 7.60)	13.8 (± 46.50)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

LDI difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	48
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.316
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-10.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-31.8
upper limit	10.53
Variability estimate	Standard error of the mean
Dispersion value	10.48

Secondary: Health Assessment Questionnaire-Disability Index (HAQ-DI)

End point title	Health Assessment Questionnaire-Disability Index (HAQ-DI)

End point description:

HAQ-DI scores included the following 3 parts:
- Eight domain scores: getting dressed, arising, eating, hygiene, walking, reaching, gripping, and activities.
- HAQ-DI total score, ranging from 0 to 3, with higher scores indicating greater dysfunction.
- Two VAS scores (which are not part of the HAQ-DI total score).

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	1.43 (± 0.514)	1.36 (± 0.622)		
Week 16	0.86 (± 0.597)	1.09 (± 0.626)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

HAQ-DI difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0009
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	-0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.44
upper limit	-0.12
Variability estimate	Standard error of the mean
Dispersion value	0.08

Secondary: Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-Fatigue)

End point title	Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-Fatigue)

End point description:

There were a total of 13 items for the FACIT-Fatigue scale. The FACIT-Fatigue scale and scoring guidelines are presented in the protocol and SAP. The FACIT-Fatigue scale ranges from 0 to 52.

A higher score indicated a better quality of life.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	27.8 (± 9.62)	26.8 (± 11.13)		
Week 16	36.0 (± 8.81)	32.2 (± 9.89)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

FACIT-Fatigue difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0086
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	3.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	5.52
Variability estimate	Standard error of the mean
Dispersion value	1.19

Secondary: 36-Item Short-Form Health Survey (SF-36)

End point title	36-Item Short-Form Health Survey (SF-36)

End point description:

The validated scoring algorithm of the SF-36 (version 2) scale was applied, which did the rescoring as well as dealt with missing items. This validated scoring algorithm resulted in standardized (0 to 100) mental and physical component scores (MCS and PCS) as well as 8 domain scores including physical functioning, physical role functioning, general health perceptions, bodily pain, vitality, social role functioning, emotional role functioning, and mental health.

A higher SF-36 score indicated a better health status.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: score on a scale				
arithmetic mean (standard deviation)				
MCS - Baseline	42.9 (± 11.59)	42.8 (± 11.39)		
MCS - Week 16	47.3 (± 11.04)	45.9 (± 12.26)		
PCS - Baseline	35.2 (± 5.87)	36.3 (± 6.97)		
PCS - Week 16	42.6 (± 7.27)	38.6 (± 6.84)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

SF-36 (MCS) difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4128
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	1.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.67
upper limit	4.04
Variability estimate	Standard error of the mean
Dispersion value	1.44

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

SF-36 (PCS) difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-squares mean difference
Point estimate	4.67

Confidence interval	
level	95 %
sides	2-sided
lower limit	2.58
upper limit	6.76
Variability estimate	Standard error of the mean
Dispersion value	1.06

Secondary: Psoriatic Arthritis Impact of Disease (PsAID)

End point title	Psoriatic Arthritis Impact of Disease (PsAID)

End point description:

PsAID was calculated using the following formula:

PsAID − 9 = PsAID1 (pain) NRS × 0.174 + PsAID2 (fatigue) NRS × 0.131 + PsAID3 (skin) NRS × 0.121 + PsAID4 (work and/or leisure activities) NRS × 0.110 + PsAID5 (function) NRS × 0.107 + PsAID6 (discomfort) NRS × 0.098 + PsAID7 (sleep) NRS × 0.089 + PsAID8 (coping) NRS × 0.087 + PsAID9 (anxiety) NRS × 0.085

Each of the 9 items was on a scale of 0 to 10, so the PsAID score also gave a number between 0 and 10.

A higher score on the PsAID indicated more impact of the disease.

End point type	Secondary

End point timeframe:

From Baseline to Week 16.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	5.8 (± 1.62)	5.7 (± 1.95)		
Week 16	3.5 (± 2.00)	4.9 (± 2.18)		

Statistical analyses

Statistical analysis title	Treatment Difference (Filgotinib 200 mg - Placebo)

Statistical analysis description:

PsAID difference in change from baseline at Week 16 (LOCF)

Comparison groups	Filgotinib v Placebo

Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Least-Squares Mean Difference
Point estimate	-1.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.12
upper limit	-0.84
Variability estimate	Standard error of the mean
Dispersion value	0.32

Secondary: Safety - TEAE (Treatment Emergent Adverse Events)

End point title	Safety - TEAE (Treatment Emergent Adverse Events)

End point description:

The number of subjects with treatment-emergent adverse events (TEAEs). An analysis of the TEAEs was performed. Laboratory assessments, 12-lead ECG and vital signs were analyzed descriptively.

End point type	Secondary

End point timeframe:

From first study drug administration until the last follow-up visit.

End point values	Filgotinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	66		
Units: Subjects				
Any TEAE	37	39		
Severe TEAE	1	5		
Serious TEAE	1	1		
Treatment related TEAE	11	9		
Discontinuation due to AE	2	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
Baseline through end of study drug treatment	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	20.1

Reporting groups	
Reporting group title	Filgotinib
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	

Serious adverse events	Filgotinib	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 65 (1.54%)	1 / 66 (1.52%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	1	0	
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 65 (0.00%)	1 / 66 (1.52%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 65 (1.54%)	0 / 66 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Filgotinib	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 65 (56.92%)	39 / 66 (59.09%)	
Investigations			

Blood cholesterol increased			
subjects affected / exposed	5 / 65 (7.69%)	0 / 66 (0.00%)	
occurrences (all)	5	0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	4 / 65 (6.15%)	0 / 66 (0.00%)	
occurrences (all)	4	0	
Blood creatine phosphokinase increased			
subjects affected / exposed	2 / 65 (3.08%)	1 / 66 (1.52%)	
occurrences (all)	2	1	
Blood glucose increased			
subjects affected / exposed	2 / 65 (3.08%)	1 / 66 (1.52%)	
occurrences (all)	2	1	
Alanine aminotransferase increased			
subjects affected / exposed	1 / 65 (1.54%)	2 / 66 (3.03%)	
occurrences (all)	1	2	
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 65 (4.62%)	5 / 66 (7.58%)	
occurrences (all)	4	7	
Dizziness			
subjects affected / exposed	2 / 65 (3.08%)	2 / 66 (3.03%)	
occurrences (all)	2	2	
Blood and lymphatic system disorders			
Lymphopenia			
subjects affected / exposed	0 / 65 (0.00%)	2 / 66 (3.03%)	
occurrences (all)	0	2	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 65 (3.08%)	2 / 66 (3.03%)	
occurrences (all)	3	2	
Abdominal pain			
subjects affected / exposed	2 / 65 (3.08%)	0 / 66 (0.00%)	
occurrences (all)	2	0	
Nausea			
subjects affected / exposed	2 / 65 (3.08%)	0 / 66 (0.00%)	
occurrences (all)	4	0	

Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	3 / 65 (4.62%)	3 / 66 (4.55%)	
occurrences (all)	3	3	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	2 / 65 (3.08%)	0 / 66 (0.00%)	
occurrences (all)	2	0	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	8 / 65 (12.31%)	10 / 66 (15.15%)	
occurrences (all)	10	11	
Urinary tract infection			
subjects affected / exposed	1 / 65 (1.54%)	2 / 66 (3.03%)	
occurrences (all)	1	2	
Metabolism and nutrition disorders			
Hyperlipidaemia			
subjects affected / exposed	2 / 65 (3.08%)	0 / 66 (0.00%)	
occurrences (all)	2	0	
Hyperglycaemia			
subjects affected / exposed	1 / 65 (1.54%)	2 / 66 (3.03%)	
occurrences (all)	1	2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 June 2017	The protocol was updated with current clinical information around serious infections and lymphoma and other malignancies in the benefit/risk assessment in accordance with the most current version of the Investigator's Brochure (Edition v 12, dated (22 May 2017). Also, an additional optional sub study in which urine and stool samples will be collected for biomarker analysis was added.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported